The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final report of an open-label phase II trial of bevacizumab plus docetaxel and gemcitabine in metastatic, previously untreated nonsquamous non-small cell lung cancer (NSCLC).
Nathan A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim; Oncogenex
Research Funding - Genentech
Sujith R. Kalmadi
Honoraria - Genentech
Marc A. Shapiro
No relevant relationships to disclose
Hamed Daw
No relevant relationships to disclose
Cristina P. Rodriguez
No relevant relationships to disclose
Abdo S. Haddad
No relevant relationships to disclose
Tara Rich
No relevant relationships to disclose
Julia Samsa
No relevant relationships to disclose
Paul Elson
No relevant relationships to disclose
Patrick C. Ma
No relevant relationships to disclose
Afshin Dowlati
No relevant relationships to disclose